215 related articles for article (PubMed ID: 9709932)
21. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.
Samojlik E; Veldhuis JD; Wells SA; Santen RJ
J Clin Invest; 1980 Mar; 65(3):602-12. PubMed ID: 6986409
[TBL] [Abstract][Full Text] [Related]
22. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
23. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
24. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa).
Giton F; de la Taille A; Allory Y; Galons H; Vacherot F; Soyeux P; Abbou CC; Loric S; Cussenot O; Raynaud JP; Fiet J
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):158-67. PubMed ID: 18337090
[TBL] [Abstract][Full Text] [Related]
25. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
[TBL] [Abstract][Full Text] [Related]
26. Aminoglutethimide as an inducer of microsomal enzymes. Part 2: Endocrine aspects.
Lønning PE; Kvinnsland S; Thorsen T; Ekse D
Breast Cancer Res Treat; 1986; 7 Suppl():S77-82. PubMed ID: 3742065
[TBL] [Abstract][Full Text] [Related]
27. Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.
Geisler J; Suzuki T; Helle H; Miki Y; Nagasaki S; Duong NK; Ekse D; Aas T; Evans DB; Lønning PE; Sasano H
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):237-41. PubMed ID: 19883757
[TBL] [Abstract][Full Text] [Related]
28. Resistance of the ovary to blockade of aromatization with aminoglutethimide.
Santen RJ; Samojlik E; Wells SA
J Clin Endocrinol Metab; 1980 Sep; 51(3):473-7. PubMed ID: 6773974
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
30. Preliminary report on progesterone effect on peripheral estrone sulfate metabolism.
Jasonni VM; Bulletti C; Franceschetti F; Ciotti P; Bonavia M; Ferraretti AP; Flamigni C
Acta Eur Fertil; 1983; 14(2):137-40. PubMed ID: 6322502
[TBL] [Abstract][Full Text] [Related]
31. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients.
Geisler J; Ekse D; Hösch S; Lønning PE
J Steroid Biochem Mol Biol; 1995 Nov; 55(2):193-5. PubMed ID: 7495698
[TBL] [Abstract][Full Text] [Related]
32. LC-MS/MS coupled with immunoaffinity extraction for determination of estrone, 17beta-estradiol and estrone 3-sulfate in human plasma.
Hosogi J; Tanaka H; Fujita K; Kuwabara T; Ikegawa S; Kobayashi N; Mano N; Goto J
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jan; 878(2):222-7. PubMed ID: 19700374
[TBL] [Abstract][Full Text] [Related]
33. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
van der Wall E; Donker TH; de Frankrijker E; Nortier HW; Thijssen JH; Blankenstein MA
Cancer Res; 1993 Oct; 53(19):4563-6. PubMed ID: 8402628
[TBL] [Abstract][Full Text] [Related]
35. Reduced conversion of dehydroepiandrosterone into estrogens in premenarchal girls.
Bulletti C; Jasonni VM; Naldi S; Cristiani P; Flamigni C
J Endocrinol Invest; 1986 Oct; 9(5):375-81. PubMed ID: 2947948
[TBL] [Abstract][Full Text] [Related]
36. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
37. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
38. Comparison of estrogen and androgen levels after oral estrogen replacement therapy.
Slater CC; Zhang C; Hodis HN; Mack WJ; Boostanfar R; Shoupe D; Paulson RJ; Stanczyk FZ
J Reprod Med; 2001 Dec; 46(12):1052-6. PubMed ID: 11789085
[TBL] [Abstract][Full Text] [Related]
39. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
40. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition.
Lønning PE; Johannessen DC; Thorsen T; Ekse D
J Steroid Biochem; 1989 Oct; 33(4A):541-5. PubMed ID: 2811363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
